GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (FRA:NV3P) » Definitions » Cyclically Adjusted Price-to-FCF

Nanoviricides (FRA:NV3P) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to . Start your Free Trial

What is Nanoviricides Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanoviricides Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Nanoviricides's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Cyclically Adjusted Price-to-FCF Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanoviricides Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanoviricides's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Nanoviricides's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cyclically Adjusted Price-to-FCF falls into.



Nanoviricides Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Nanoviricides's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nanoviricides's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.155/131.7762*131.7762
=-0.155

Current CPI (Mar. 2024) = 131.7762.

Nanoviricides Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.701 100.560 -0.919
201409 -0.631 100.428 -0.828
201412 -1.622 99.070 -2.157
201503 -0.725 99.621 -0.959
201506 -0.731 100.684 -0.957
201509 -0.619 100.392 -0.813
201512 -0.397 99.792 -0.524
201603 -0.820 100.470 -1.076
201606 -0.440 101.688 -0.570
201609 -0.689 101.861 -0.891
201612 -0.851 101.863 -1.101
201703 -0.658 102.862 -0.843
201706 -0.298 103.349 -0.380
201709 -0.421 104.136 -0.533
201712 -0.391 104.011 -0.495
201803 -0.362 105.290 -0.453
201806 -0.878 106.317 -1.088
201809 -0.247 106.507 -0.306
201812 -0.552 105.998 -0.686
201903 -0.496 107.251 -0.609
201906 -0.388 108.070 -0.473
201909 -0.340 108.329 -0.414
201912 -0.263 108.420 -0.320
202003 -0.333 108.902 -0.403
202006 -0.183 108.767 -0.222
202009 -0.184 109.815 -0.221
202012 -0.179 109.897 -0.215
202103 -0.119 111.754 -0.140
202106 -0.167 114.631 -0.192
202109 -0.055 115.734 -0.063
202112 -0.177 117.630 -0.198
202203 -0.133 121.301 -0.144
202206 -0.121 125.017 -0.128
202209 -0.094 125.227 -0.099
202212 -0.118 125.222 -0.124
202303 -0.144 127.348 -0.149
202306 -0.119 128.729 -0.122
202309 -0.094 129.860 -0.095
202312 -0.135 129.419 -0.137
202403 -0.155 131.776 -0.155

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nanoviricides  (FRA:NV3P) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Nanoviricides Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (FRA:NV3P) Business Description

Industry
Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides (FRA:NV3P) Headlines

No Headlines